Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital

May 13, 2014 6:26 AM

BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $24 price target on Halozyme Therapeutics (NASDAQ: HALO) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found